HABP / VABP

Hospital-Acquired Bacterial Pneumonia

 

Acute Pneumonia from Infection by Multidrug-Resistant Bacteria– A Growing Concern

 

Infections acquired in hospital settings, such as Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP), affect an estimated 10% of all hospitalized patients, causing pneumonia, urinary tract infections, and bloodstream infections. These infections cause significant morbidity and mortality, and high economic burden to third-party payers and society. According to an estimate from the U.S. Centers for Disease Control and Prevention (CDC), infections acquired in hospitals cost more than $30 billion per year.

 

Hospital-acquired infections (HAI) are transmitted through direct contact from hospital staff, patient-to-patient transmission, inadequately sterilized instruments, and invasive interventions. Bacteria cause most HAIs, with Staphylococcus aureus and Pseudomonas aeruginosa ranking among the top causative pathogens of HAI. It is estimated that more than 2 million HAI occur annually in the U.S. and about 1.2 million occur in Europe. Moreover, the steady rise in antibiotic resistance within the last decade has dramatically increased the medical burden associated with HAI.

 

Patients in the Intensive Care Unit (ICU) contract HAI more frequently than those in the standard hospital ward, and infections in the ICU are increasingly caused by multidrug-resistant (MDR) P. aeruginosa and S. aureus bacteria, leading to extended, costly stays in the ICU with life-threatening infections. VABP and bloodstream infections have particularly poor prognoses, with an associated mortality of up to 40%. In light of this increasing problem, there is a significant need for new therapeutic options to fight P. aeruginosa and S. aureus infections.

 

Current Treatment of Hospital-Acquired Infections

 

The current standard of care for hospital-acquired infections is antibiotic therapy, many times given as a combination of up to three different drugs. However, the recent emergence of virulent, antibiotic-resistant bacteria has severely limited the effectiveness of modern antibiotics, leading to increased morbidity and mortality. Recent reports indicate that up to 60% of infections are resistant to the best antibiotics available. This is especially true for P. aeruginosa and S. aureus (e.g. Methicillin-resistant Staphylococcus aureus, MRSA), which are among the bacteria being targeted by Aridis’ monoclonal antibodies.

 

Advantages of Monoclonal Antibodies as Anti-Infectives

 

Combining monoclonal antibody (mAb) treatment with antibiotics can lead to more rapid resolution of infection, resulting in shorter stays in the ICU and a significant reduction of morbidity, mortality, and health care costs.

 

Arguably, antibodies are the most critical component of the human immune response, targeting and eliminating invading pathogens. The advantages to using therapeutic mAbs in combination with current antibiotic therapy are several fold:

 

  • Synergistic in potency and broader coverage compared to either therapy alone
  • Generally safe and well tolerated
  • Exhibit a significantly longer in vivo half-life than antibiotics (up to three weeks vs. hours), resulting in less frequent dosing

 

 

The adjunctive treatment paradigm of using monoclonal antibodies with standard of care antibiotics is potentially transformational and offers an important treatment option for hospital acquired infections and to combat the emerging healthcare challenges associated with antimicrobial resistance.

 

Aridis’ suite of innovative monoclonal antibodies is well positioned to be first-to-market and demonstrate a compelling pharmacoeconomic value.

HABP-VABP